We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche (RHHBY - Free Report) announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for its arthritis drug Actemra.
The sBLA is seeking approval for the intravenous formulation of the drug for the treatment of COVID-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation.
The regulatory body has granted Priority Review to the sBLA and a decision on the same is expected in the second half of this year.
The sBLA submission is based on results from four studies ((EMPACTA, COVACTA, REMDACTA, and RECOVERY) that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalized patients. These studies suggested that Actemra/RoActemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support.
We remind investors that Actemra/RoActemra received Emergency Use Authorization (EUA) from the FDA and is currently approved for use in 16 countries for defined patients hospitalized with severe or critical COVID-19.
Actemra/RoActemra is also approved for the treatment of COVID-19 in the European Union.
Earlier in 2022, the World Health Organization (WHO) prequalified Actemra/RoActemra for patients with severe or critical COVID-19, supporting access to care in low- and middle-income countries.
Following the emergence of the Omicron variant, the WHO reported that interleukin-6 receptor blockers, such as Actemra/RoActemra, are expected to be still effective for managing patients with severe COVID-19.
We note that Actemra/RoActemra is approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide relief. The subcutaneous injection is approved for the treatment of adult patients with giant cell arteritis (GCA) for the treatment of patients two years of age and older with active polyarticular juvenile idiopathic arthritis (PJIA) or active systemic juvenile idiopathic arthritis (SJIA).
Roche’s stock has gained 0.7% in the year so far compared with the industry’s growth of 3.7%.
Image Source: Zacks Investment Research
The sudden emergence of COVID-19 forced many pharma/biotech companies to evaluate the efficacy of existing drugs for treating infected patients during the outbreak.
We note that Gilead’s (GILD - Free Report) Veklury was approved by the FDA for adults and pediatric patients 12 years of age and older and weighing at least 40 kg for the treatment of COVID-19 requiring hospitalization. The FDA also approved expanded Veklury’s label for treating non-hospitalized adult and adolescent patients at high risk of progression to severe COVID-19, including hospitalization or death.
Gilead also released data that demonstrated the in vitro activity of antiviral treatment for COVID-19, Veklury (remdesivir), against 10 SARS-CoV-2 variants, including the highly-contagious Omicron.
The FDA earlier revised the authorizations for two monoclonal antibody treatments – Eli Lilly’s (LLY - Free Report) bamlanivimab and etesevimab (administered together) and Regeneron’s (REGN - Free Report) REGEN-COV (casirivimab and imdevimab).
Data indicated that these treatments are highly unlikely to be active against the Omicron variant, which is the dominant one in the United States.
The regulatory body stated that these treatments are no longer authorized for use in any U.S. states, territories and jurisdictions at this time.
Sales of REGEN-COV had significantly boosted the top line of Regeneron and this revision will adversely impact sales for now.
The regulatory body also issued a EUA to Lilly’s bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.
Image: Bigstock
Roche (RHHBY) Actemra Application Receives Priority Review
Roche (RHHBY - Free Report) announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for its arthritis drug Actemra.
The sBLA is seeking approval for the intravenous formulation of the drug for the treatment of COVID-19 in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation.
The regulatory body has granted Priority Review to the sBLA and a decision on the same is expected in the second half of this year.
The sBLA submission is based on results from four studies ((EMPACTA, COVACTA, REMDACTA, and RECOVERY) that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalized patients. These studies suggested that Actemra/RoActemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support.
We remind investors that Actemra/RoActemra received Emergency Use Authorization (EUA) from the FDA and is currently approved for use in 16 countries for defined patients hospitalized with severe or critical COVID-19.
Actemra/RoActemra is also approved for the treatment of COVID-19 in the European Union.
Earlier in 2022, the World Health Organization (WHO) prequalified Actemra/RoActemra for patients with severe or critical COVID-19, supporting access to care in low- and middle-income countries.
Following the emergence of the Omicron variant, the WHO reported that interleukin-6 receptor blockers, such as Actemra/RoActemra, are expected to be still effective for managing patients with severe COVID-19.
We note that Actemra/RoActemra is approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide relief. The subcutaneous injection is approved for the treatment of adult patients with giant cell arteritis (GCA) for the treatment of patients two years of age and older with active polyarticular juvenile idiopathic arthritis (PJIA) or active systemic juvenile idiopathic arthritis (SJIA).
Roche’s stock has gained 0.7% in the year so far compared with the industry’s growth of 3.7%.
Image Source: Zacks Investment Research
The sudden emergence of COVID-19 forced many pharma/biotech companies to evaluate the efficacy of existing drugs for treating infected patients during the outbreak.
We note that Gilead’s (GILD - Free Report) Veklury was approved by the FDA for adults and pediatric patients 12 years of age and older and weighing at least 40 kg for the treatment of COVID-19 requiring hospitalization. The FDA also approved expanded Veklury’s label for treating non-hospitalized adult and adolescent patients at high risk of progression to severe COVID-19, including hospitalization or death.
Gilead also released data that demonstrated the in vitro activity of antiviral treatment for COVID-19, Veklury (remdesivir), against 10 SARS-CoV-2 variants, including the highly-contagious Omicron.
The FDA earlier revised the authorizations for two monoclonal antibody treatments – Eli Lilly’s (LLY - Free Report) bamlanivimab and etesevimab (administered together) and Regeneron’s (REGN - Free Report) REGEN-COV (casirivimab and imdevimab).
Data indicated that these treatments are highly unlikely to be active against the Omicron variant, which is the dominant one in the United States.
The regulatory body stated that these treatments are no longer authorized for use in any U.S. states, territories and jurisdictions at this time.
Sales of REGEN-COV had significantly boosted the top line of Regeneron and this revision will adversely impact sales for now.
The regulatory body also issued a EUA to Lilly’s bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.
Roche currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.